D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Authors:
- Guochuan E. TsaiGuochuan E. Tsai
- Pinchen YangPYPinchen Yang
- Yue-Cune ChangYCYue-Cune Chang
- Mian-Yoon ChongMCMian-Yoon Chong
- 1 February 2006
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 59 (3) , 230-234
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patientsPsychopharmacology, 2004
- Neuropsychological Correlates of the PANSS Cognitive FactorPsychopathology, 2004
- Identification and Characterization of a Novel Member of the Heterodimeric Amino Acid Transporter Family Presumed to be Associated with an Unknown Heavy ChainJournal of Biological Chemistry, 2001
- A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With SchizophreniaArchives of General Psychiatry, 1999
- Evaluation of Treatment-Resistant SchizophreniaSchizophrenia Bulletin, 1997
- The Glutamatergic Dysfunction Hypothesis for SchizophreniaHarvard Review of Psychiatry, 1996
- The Phencyclidine-Glutamate Model of SchizophreniaClinical Neuropharmacology, 1995
- Free D-aspartate and D-alanine in normal and Alzheimer brainBrain Research Bulletin, 1991
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989
- A “Glutamatergic Hypothesis” of SchizophreniaClinical Neuropharmacology, 1989